Cargando…
CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) prior to and post surgery has been reported across various solid tumors. We initiated a new type of adaptive platform t...
Autores principales: | Taniguchi, Hiroya, Nakamura, Yoshiaki, Kotani, Daisuke, Yukami, Hiroki, Mishima, Saori, Sawada, Kentaro, Shirasu, Hiromichi, Ebi, Hiromichi, Yamanaka, Takeharu, Aleshin, Alexey, Billings, Paul R., Rabinowitz, Matthew, Oki, Eiji, Takemasa, Ichiro, Kato, Takeshi, Mori, Masaki, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253296/ https://www.ncbi.nlm.nih.gov/pubmed/33931919 http://dx.doi.org/10.1111/cas.14926 |
Ejemplares similares
-
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2023) -
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy
por: Miyo, Masaaki, et al.
Publicado: (2022) -
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021) -
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
por: Kasi, Pashtoon M., et al.
Publicado: (2022) -
A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2019)